An interventional study of Notification Group and No Notification Group in Iron Deficiency (ID), Heart Failure and Heart Failure and Reduced Ejection Fraction, sponsored by Kaiser Permanente. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Kaiser Permanente · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Iron Deficiencies with a site in United States — 16 open to participants now, 20 under way, 4 of them phase 3. Iron Deficiencies · United States.
Among the 82 studies in Iron Deficiencies with a site in United States, this one is the 5th largest by planned enrollment of the 63 interventional ones that give a count, is one of 8 that started in 2026, is one of 29 with no phase, reaches primary completion later than 13 of the 19 other live ones, and was the 77th registered.
386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.
Browse Iron Deficiencies studies →16 of the 82 studies in Iron Deficiencies with a site in United States are open now. Recruiting first, the newest first:
Qualia Life Sciences · Sites in United States
Ages 18+ · Healthy volunteers
Lindenwood University · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Pennington Biomedical Research Center · Sites in United States
Ages 18–50 · Healthy volunteers
University of Illinois Chicago · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Columbia University · Sites in United States
Ages 10–19
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 14 · Phase 4 10
First in 2000; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 99 across 301 interventional studies indexed under Iron Deficiencies.
Median enrollment 89 across the 63 interventional studies, 73 across the 18 observational. Of the 57 that completed or were terminated, 13 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 82 have an industry lead sponsor. The 10 most frequent:
Kaiser Permanente is the lead sponsor of 393 studies on the registry; 43 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
Kaiser Permanente has 1 study filed under Iron Deficiencies — fewer than ten, so there is no comparison to draw.
10 of the studies in Iron Deficiencies with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179226Phase 3Pharmacosmos A/SMulti-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia | 2027-04-30 |
| NCT07217873Phase 3Columbia UniversityIntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study | 2027-08-31 |
| NCT06527391Phase 3University of MinnesotaCholine and Iron Deficiency | 2027-09-21 |
| NCT07197905Vanderbilt University Medical CenterRestoring Iron Deficiency in POTS | 2026-12 |
| NCT07892911Ancestral Supplements, LLCA Study to Evaluate the Effects of a Beef Liver Supplement on Energy, Mood, and Mental Clarity | 2026-12-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 82 studies in Iron Deficiencies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The INITIATE-HF study is a cluster randomized controlled trial that aims to find out if reminding doctors about treatment guidelines for iron deficiency in adults with heart failure who are hospitalized and have evidence of iron deficiency changes the subsequent use of intravenous (IV) iron.
Two groups of hospitalized adult patients with known heart failure and iron deficiency will be compared:
The study will measure if this provider-facing notification affects physician use of recommended IV iron treatment in eligible patients with heart failure, left ventricular ejection fraction less than 50%, and iron deficiency. Secondarily, if there is an increased use of IV iron observed in the intervention group, this study will evaluate whether there are differential health outcomes (i.e., fewer subsequent hospital visits and lower risk of death) of patients whose providers were assigned to the intervention group.
The INITIATE-HF study will be managed at the Kaiser Permanente Northern California (KPNC) Division of Research and will include participants from KPNC medical centers. Up to 21 medical centers will be randomly assigned into two groups, with balanced populations between the groups based on demographic and heart failure-related characteristics. In medical centers assigned to the intervention group, physicians of eligible patients with heart failure and iron deficiency (i.e., TSAT \<20%) will be sent information from current KPNC and national clinical practice guidelines about the use of IV iron therapy in the setting of heart failure. In medical centers assigned to the control group, physicians will not be contacted about their patients with iron deficiency or receive information about current guidelines about the use of IV iron (i.e., usual care). If a patient with heart failure is admitted to a medical center assigned to the intervention group and has iron deficiency, their treating doctor will be notified about their patient's iron stores lab results, information from KPNC and national guidelines about the use of IV iron therapy, and details about the available IV iron formulations and recommended dosages for their consideration. The study team will not have any direct contact with patients at any of the medical centers assigned to either the intervention or control group and will not be involved in any clinical care decision-making for any patients, as that will reside with each patient's responsible physician and care team.
The intention-to-treat (ITT) population will consist of patients meeting all eligibility criteria at both intervention and control sites. The per-protocol population will include data from all patients at intervention sites. All primary and secondary endpoints will be analyzed using mixed effects Cox proportional hazards regression for point and interval estimation of the intervention effect on the primary outcome and on each of the secondary outcomes. Similarly, mixed effects Poisson regression will be additionally performed to analyze the effect of the intervention in relation to secondary outcomes when characterized as counts: all-cause and heart failure-specific outpatient encounters (i.e., clinic and telehealth visits), emergency department visits, and hospitalizations.
Interaction analyses will be performed to assess for potential heterogeneity of treatment effects based on the following prespecified subgroups: age, sex, race/ethnicity, presumed etiology of heart failure (i.e., ischemic vs. non-ischemic), duration of diagnosed heart failure (i.e., \<1 vs. >1 year), reason for hospital admission (i.e., primary vs. secondary discharge diagnosis for heart failure), left ventricular ejection fraction category (\<40% vs. 41-49%), B-type natriuretic peptide (BNP) level (i.e., \< vs. > the median value), TSAT (i.e., \<15% vs. 15-19%), estimated glomerular filtration rate (eGFR) level (i.e., \< vs. > the median), hemoglobin level (i.e., \< vs. > the median), anemia status, and KPNC service area.
The primary analysis will focus on the implementation outcome of the administration of IV iron during the index hospitalization to determine how the provider-facing notification influences provider behavior and care processes. The secondary analysis will evaluate effectiveness outcomes, including the composite of all-cause death and heart failure-related hospitalization, to determine whether any observed changes in the implementation process outcome also translate into improved patient clinical outcomes up through 12 months after randomization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults (age >18 years); Diagnosed heart failure with most recent \<50%; Hospitalized for any reason for the index admission; Documented iron deficiency defined as TSAT \<20% during the index hospitalization; At least 6 months of health plan coverage and prescription drug benefit before admission
Exclusion Criteria:
A documented allergy to IV iron in the Kaiser Permanente Northern California (KPNC) electronic health record (EHR) system; A history of hemochromatosis (i.e., iron overload) based on KPNC EHR data; End-stage kidney disease (defined as receiving chronic dialysis or a prior kidney transplant) or advanced chronic kidney disease (i.e., estimated [eGFR] \<30 mL/min/1.73 m2) based on most recent pre-admission outpatient laboratory results or the KPNC regional End-Stage Kidney Disease Treatment Registry; Serum ferritin >300 ng/mL based on KPNC EHR data; Diagnosed with cancer and/or receiving systemic chemotherapy based on KPNC EHR data; Institutionalized (e.g., prison) and/or receiving palliative care per KPNC EHR data
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In medical centers assigned to the intervention group, physicians of eligible patients will be sent a one-time notification with information about their patient's iron deficiency, current KPNC and national clinical practice guidelines about IV iron therapy, and available IV iron formulations and recommended dosages.
Other: Notification Group
In medical centers assigned to the control group, physicians of eligible patients will NOT be sent information about their patients or current KPNC and national clinical practice guidelines about the use of IV iron therapy in the setting of heart failure.
Other: No Notification Group
In medical centers assigned to the intervention group within the INITIATE-HF study, physicians of eligible patients with HF and iron deficiency will be sent information from current KPNC and national guidelines about IV iron therapy.
In medical centers assigned to the control group, physicians will not receive information about current guidelines about the use of IV iron (i.e., usual care).
% of patients receiving IV iron within 7 days of hospital admission
The primary outcome is the implementation outcome of the percentage of patients who receive IV iron within 7 days of hospitalization to determine how the provider-facing notification influences provider behavior and care processes.
Time frame: From the day of confirmed eligibility up to 7 days later
% of patients who experience the composite outcome of all-cause death and heart failure-related hospitalization
The secondary outcome will be a percentage of patients who experience the composite outcome of all-cause death and heart failure-related hospitalization, to determine whether any observed changes in the implementation process outcome also translate into improved patient outcomes during the 12 months after randomization.
Time frame: From randomization to the end of 12 months after randomization
Plan to share: Yes — De-identified individual participant data underlying the results of this trial will be considered for sharing with qualified researchers. Requests must include a scientifically sound proposal and documentation of IRB approval or exemption. Data access will be subject to review and execution of an appropriate data use agreement to protect participant privacy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Requests for IPD will be considered starting 6 months after publication of the primary results of the study, with an end date of 10 years after study closure. Supporting information will be available as of 09 MAR 2026, with no end date.
Access criteria: De-identified individual participant data underlying the results of this trial will be considered for sharing with qualified researchers. Requests must include a scientifically sound proposal and documentation of IRB approval or exemption. Data access will be subject to review and execution of an appropriate data use agreement to protect participant privacy. There will be no restriction to access supporting information.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.
Of 77 non-industry interventional studies with no phase under Iron Deficiencies, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 20 months is above that.
Counting every sponsor, half of 89 studies reached it within 10 months; a quarter within 5 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.